Relationship between severity of essential hypertension and hyperuricemia;Relación entre la gravedad de la hipertensión arterial esencial y la prevalencia de hiperuricemia

Medicina Clinica

Volumn 117, Issue 3, 2001, Pages 85-89

  Campo, Carlos ^a   García Puig, Juan ^b   Segura, Julian ^a   Alcázar, José María ^a   García Robles, Rafael ^c   Ruilope, Luis M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Essential hipertensi n; Hyperuricemia; Renal function; Serum uric acid; Target organ damage

Indexed keywords

URIC ACID;

ADULT; ARTICLE; BLOOD; BLOOD PRESSURE; COHORT ANALYSIS; FEMALE; HOSPITALIZATION; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; SEX DIFFERENCE;

ADULT; BLOOD PRESSURE; COHORT STUDIES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; SEVERITY OF ILLNESS INDEX; SEX FACTORS; URIC ACID;

EID: 1642512698     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(01)72025-8     Document Type: Article

References (43)

1. Breckenridge A. Hypertension and hyperuricaemia. Lancet 1966; 1: 15-18.
2. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal disease. N Eng J Med 1966; 275: 457-464.
3. García Puig J, Ruilope LM. Uric acid as a cardiovascular risk factor. J Hypertens 1999; 17: 869-872.
4. Ward HJ. Uric acid as an independent risk factor in the treatment of hypertension [fe de rrores en: Lancet 1998; 352: 912]. Lancet 1998; 352: 670-671.
5. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality. The NHANES I epidemiologic follow-up study, 1971-1992. JAMA 2000; 283: 2404-2410.
6. Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34: 144-150.
7. Klein R, Klein BE, Cornni JC, Maready J, Cassel JC, Tyroler HA. Serum uric acid. Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Intern Med 1973; 132: 401-410.
8. The Coronary Drug Project Research Group. Serum uric acid: Its association with other risk factors and with mortality in coronary heart disease. J Chron Dis 1976; 29: 557-569.
9. Persky VW, Dyer AR, Idris-Soven E, Stamler J, Shekelle RB, Schoenberger JA. Uric acid: a risk factor for coronary heart disease? Circulation 1979; 59: 969-977.
10. Fessel WJ. High uric acid as an indicator of cardiovascular disease. Independence from obesity. Am J Med 1980; 68: 401-404.
11. Yano K, Reed DM, McGee DL. Ten-year incidence of coronary heart disease in the Honolulu Heart Program. Relationship to biologic and lifestyle characteristics. Amm J Epidemiol 1984; 119: 653-666.
12. Brand FN, McGee DL, Kannel WB, Stokes JD, Castelli WP. Hyperuricemia as a risk factor of coronary heart disease: the Framingham Study. Am J Epidemiol 1985; 121: 11-18.
13. Bengtsson C, Lapidus L, Stendahl C, Waldenstrom J. Hyperuricaemia and risk of acrdiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Med Scand 1988; 224: 549-555.
14. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J. Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol 1989; 42: 257-267.
15. Woo J, Swaminathan, Cockram C, Lau E, Chan A. Association between serum uric acid and some cardiovascular risk factors in a Chinese population. Postgrad Med J 1994; 70: 486-491.
16. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995; 141: 637-644.
17. Lee J, Sparrow D, Vokonas PS, Landsberg L, Weiss ST. Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome. The Normative Aging Study. Am J Epidemiol 1995; 142: 288-294.
18. Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. Heart 1997; 78: 147-153.
19. Lehto S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 1998; 29: 635-639.
20. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7-13.
21. Hollenberg NK. Literature alert. Curr Hypertens Rep 2000; 2: 5-8.
22. Alcázar J, Ruilope L, Ladrón de Guevara P, Barrientos A, Millet VG, Bello I et al. Hiperuricemia e hipertensión arterial esencial. Nefrología 1982; 2: 145-149.
23. Kelley WN. Hyperuricemia. En: Kelley WN, Harris ED, Ruddy S, Sledge CB, editores. Textbook of rheumatology. Filadelfia: W.B. Saunders, Co., 1989; 571-578.
24. Mikkelsen WM, Dodge HJ, Vallkenburg H. The distribution of serum uric acid values in a population unselected as to gout or hyperuricemia: Tecumseh, Michigan, 1959-1960. Am J Med 1965; 39: 242-251.
25. Keith NM, Wagener HP, Barker MW. Some different types of essential hypertension: their course and prognosis. Am J Med Sci 1939; 197: 332-343.
26. Roose GA, Blackburn H. Cardiovascular Survey Methods. Ginebra: World Health Organization Monograph Series, No. 56; 1968: 1-188.
27. Kannel WB. Risk stratification in hypertension: new concepts from Framingham. Am J Hypertens 2000; 13: S3-S10.
28. Messerli FH, Frohlich ED, Dreslinski GR, Suárez DH, Aristimuno GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980; 93: 817-821.
29. Ruilope LM, Campo C, Rodriguez-Artalejo F, Lahera V, García-Robles R, Rodicio JL. Blood pressure and renal function: therapeutic implications. J Hypertens 1996; 14: 1259-1263.
30. Mattei P, Arzilli F, Giovannetti R, Penno G, Arrighi P, Taddei S. Microalbuminuria and renal haemodynamics in essential hypertension. Eur J Clin Invest 1997; 27: 755-760.
31. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - The role of insulin resistance and the sympathoadrenal system N Eng J Med 1996; 334: 374-381.
32. Tracy RE, Strong JP, Newman WP III, Malcom GT, Oalmann MC, Guzman MA. Renovasculopathies of nephrosclerosis in relation to atherosclerosis at ages 25-54 years. Kidney Int 1996; 49: 564-570.
33. Capuccio FP, Strazzullo P, Farinaro E, Trevisan M. Uric acid metabolism and tubular sodium handling. Results from a population-based study. JAMA 1993; 270: 354-359.
34. Quinones-Galvan A, Ferrannini E. Renal effects of insulin in man. J Nephrol 1997; 10: 188-191.
35. Kerkalainen P, Sarlund H, Laakso M. Long-term association of cardiovascular risk factors with impaired insulin secretion and insulin resistance. Metabolism 2000; 49: 1247-1254.
36. Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemic related to decreased urate secretion. Nephron 1991; 59: 364-368.
37. De Wardener HE. The primary role of the kidney and salt intake in the etiology of essential hypertension: part I. Clin Sci 1990; 79: 193-200.
38. Franse LV, Pahor M, Di Bari M, Shorr RI, Wan JY, Somes GW et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18: 1149-1154.
39. Langford HG, Blaufox MD, Borhani NO, Curb JD, Molteni A, Schneider KA et al. Is thaizide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med 1987; 147: 645-649.
40. Shulman NB, Ford CE, Hall WD, Blaufox D, Simon D, Langford HG et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the Hypertension Detection and Follow-up Program. Hypertension 1989; 13 (Supl 1): I-80-I-93.
41. Hansson L, Zanchetti A, Carruthers SG, for the HOT Study Group. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762.
42. Brown MJ, Palmer CR, Castaigne A, De Leeuw PW, Mancia G, Rosental T et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a goal in hypertension treatment. Lancet 2000; 356: 366-372.
43. Culleton BF. Uric acid and cardiovascular disease: a renal-cardiac relationship? Curr Opin Nephrol Hypertens 2001; 10: 371-375.